Therapeutic Asset Ratings

243 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Lansoprazole Lymphoma	Sherief Abd-Elsalam	P3	CCC (52)
Lapelga Lymphoma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (52)
L-Dep Lymphoma	Beijing Friendship Hospital	P3	CCC (52)
Oxycodone Lymphoma	St. Louis University	P3	CCC (52)
OXYCODONE HYDROCHLORIDE, HYDROCODONE- Lymphoma	St. Louis University	P3	CCC (52)
Zilovertamab Lymphoma	Oncternal Therapeutics, Inc	P3	CCC (52)
Axicabtagene Ciloleucel Lymphoma	The First Affiliated Hospital of Xiamen University	P2	CCC (52)
cd22 car-transduced t cells Lymphoma	Liping Dou	P2	CCC (52)
Dasatinib Lymphoma	National Cancer Institute (NCI)	P2	CCC (52)
Decitabine Lymphoma	Mayo Clinic	P2	CCC (52)
Lorazepam Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CCC (52)
Polatuzumab Lymphoma	Jennifer Crombie, MD	P2	CCC (52)
Pyrotinib Lymphoma	Won Seog Kim	P2	CCC (52)
rc48-adc Lymphoma	Won Seog Kim	P2	CCC (52)
Tislelizumab Lymphoma	Won Seog Kim	P2	CCC (52)
TRASTUZUMAB Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (52)
RIFALDAZINE Lymphoma	Hutchmed	P1	CCC (52)
Lactobacillus Plantarum Strain 299V Lymphoma	Children's Oncology Group	P3	CCC (51)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Lymphoma	Leland Metheny	P2	CCC (51)
HUMAN IMMUNOGLOBULINS Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CCC (51)
Jcar017 (Lisocabtagene Maraleucel) Lymphoma	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	P2	CCC (51)
cd19-ucart Lymphoma	University Hospital Tuebingen	P1/2	CCC (51)
ALECTINIB Lymphoma	Cancer Research UK	P2/3	CCC (50)
shr2554 Lymphoma	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CCC (49)
[18F]F-RESCA-R8B4 Lymphoma	RenJi Hospital	P2	CCC (48)

Showing 101 to 125 of 243 assets

PreviousPage 5 of 10Next